Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model
This article was originally published in Start Up
Executive Summary
In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding.
You may also be interested in...
Sequella TB Drug Deal Blurs The Line Between Licensing And Financing
For a small biotech seeking to out-license a promising asset in a far-flung territory, established pharmas typically make the best partners, given these big players have the infrastructure required to gain regulatory approval for a compound and bring it to market. But for Sequella Inc., a Rockville, MD-based infectious disease specialist, the commercial path of its tuberculosis drug in Russia and other former Soviet republics goes through a partner that will likely never sell the drug itself.
Sequella TB Drug Deal Blurs The Line Between Licensing And Financing
For a small biotech seeking to out-license a promising asset in a far-flung territory, established pharmas typically make the best partners, given these big players have the infrastructure required to gain regulatory approval for a compound and bring it to market. But for Sequella Inc., a Rockville, MD-based infectious disease specialist, the commercial path of its tuberculosis drug in Russia and other former Soviet republics goes through a partner that will likely never sell the drug itself.